IRIDEX Corporation (IRIX) Insider Trading Activity

NASDAQ$0.7101+0.01 (1.44%)
Market Cap
$12.23M
Sector
Healthcare
Industry
Medical—Devices
Rank in Sector
159 of 849
Rank in Industry
25 of 107

IRIX Insider Trading Activity

IRIX Median Price and Trade Amounts History Chart

Statistics of Insider Transactions

Amount of Insider Buys and Sells

Buys
$660,457
75
100
Sells
$0
0
0

Related Transactions

Lin Shih-Yao David10 percent owner
39
$509,544
0
$0
$509,544
Dizon Romeo RChief Financial Officer
30
$100,561
0
$0
$100,561
MOORE WILLIAM Mdirector
6
$50,352
0
$0
$50,352

About IRIDEX Corporation

IRIDEX Corporation is a medical technology firm specializing in ophthalmology. They develop and supply advanced therapeutic laser systems, various delivery instruments, and essential consumable tools designed to address vision-threatening ocular conditions. Their product portfolio includes several laser consoles, each tailored for specific eye conditions. The Cyclo G6 system is specifically engineered for glaucoma treatment. For ailments like diabetic macular edema and other retinal pathologies, IRIDEX provides the IQ 532 and IQ 577 laser …

Insider Activity of IRIDEX Corporation

Over the last 12 months, insiders at IRIDEX Corporation have bought $660,457 and sold $0 worth of IRIDEX Corporation stock.

On average, over the past 5 years, insiders at IRIDEX Corporation have bought $578,802 and sold $0 worth of stock each year.

Highest buying activity among insiders over the last 12 months: Lin Shih-Yao David (10 percent owner) — $509,544. Dizon Romeo R (Chief Financial Officer) — $100,561. MOORE WILLIAM M (director) — $50,352.

The last purchase of 7,900 shares for transaction amount of $4,977 was made by Dizon Romeo R (Chief Financial Officer) on 2026‑09‑16.

List of Insider Buy and Sell Transactions, IRIDEX Corporation

2026-09-16PurchaseDizon Romeo RChief Financial Officer
7,900
0.0474%
$0.63
$4,977
+19.07%
2026-09-14PurchaseDizon Romeo RChief Financial Officer
2,354
0.0138%
$0.65
$1,530
+11.98%
2026-09-10PurchaseDizon Romeo RChief Financial Officer
5,100
0.0297%
$0.68
$3,468
+4.27%
2026-08-24PurchaseDizon Romeo RChief Financial Officer
6,668
0.0385%
$0.75
$4,999
-5.29%
2026-06-12PurchaseDizon Romeo RChief Financial Officer
975
0.0057%
$1.14
$1,110
-26.42%
2026-06-11PurchaseDizon Romeo RChief Financial Officer
1,675
0.0098%
$1.14
$1,910
-26.42%
2026-06-08PurchaseDizon Romeo RChief Financial Officer
2,400
0.0139%
$1.12
$2,688
-25.73%
2026-06-05PurchaseDizon Romeo RChief Financial Officer
2,521
0.0153%
$1.15
$2,899
-24.34%
2026-06-03PurchaseDizon Romeo RChief Financial Officer
2,400
0.0138%
$1.17
$2,808
-28.02%
2026-05-26PurchaseDizon Romeo RChief Financial Officer
5,004
0.0285%
$1.00
$5,004
-19.16%
2026-03-30PurchaseLin Shih-Yao David10 percent owner
7,371
0.0429%
$0.99
$7,297
-6.05%
2026-03-24PurchaseLin Shih-Yao David10 percent owner
4,549
0.0253%
$1.33
$6,050
-29.66%
2026-03-23PurchaseLin Shih-Yao David10 percent owner
17,526
0.1004%
$1.33
$23,310
-29.61%
2026-03-17PurchaseLin Shih-Yao David10 percent owner
22,805
0.1307%
$1.31
$29,872
-25.93%
2026-03-16PurchaseLin Shih-Yao David10 percent owner
1,682
0.0096%
$1.30
$2,187
-25.56%
2026-03-12PurchaseLin Shih-Yao David10 percent owner
967
0.0056%
$1.32
$1,276
-25.56%
2026-03-06PurchaseDizon Romeo RChief Financial Officer
1,110
0.0066%
$1.26
$1,399
-19.36%
2026-03-03PurchaseLin Shih-Yao David10 percent owner
752
0.0044%
$1.42
$1,068
-29.72%
2026-03-02PurchaseLin Shih-Yao David10 percent owner
1,424
0.0083%
$1.40
$1,994
-28.37%
2026-02-23PurchaseLin Shih-Yao David10 percent owner
14,943
0.0869%
$1.41
$21,070
-28.37%
Total: 474
*Gray background shows transactions not older than one year

Insider Historical Profitability

3.01%
Lin Shih-Yao David10 percent owner
1186809
6.7567%
$826,019.06900
<0.0001%
MOORE WILLIAM Mdirector
251550
1.4321%
$175,078.80640
+9.84%
Dizon Romeo RChief Financial Officer
185306
1.055%
$128,972.98758
<0.0001%
BlueLine Catalyst Fund IX, L.P.
2559122
14.5695%
$1.78M180
+10.82%
BlueLine Capital Partners II, L.P.10 percent owner
2508100
14.279%
$1.75M20
+27.27%
BlueLine Partners, L.L.C.10 percent owner
2465222
14.0349%
$1.72M90
Acuta Capital Fund, LP10 percent owner
1344720
7.6557%
$935,925.12330
<0.0001%
PARAGON ASSOCIATES & PARAGON ASSOCIATES II JOINT VENTURE
1320000
7.515%
$918,720.00170
+39.25%
Mercer PatrickPresident and CEO
386730
2.2017%
$269,164.0830
+1.7%
BOUTACOFF THEODORE APresident, CEO and Chairman
159047
0.9055%
$110,696.71119
Shuda Scottdirector
129523
0.7374%
$90,148.0130
+0.42%
Grove Robert Earledirector
93364
0.5315%
$64,981.3480
+0.21%
HUSS BEVERLY Adirector
92639
0.5274%
$64,476.7410
<0.0001%
NAUMANN-ETIENNE RUEDIGERdirector
64433
0.3668%
$44,845.37411
+37.2%
Mackaness James HCFO and COO
45052
0.2565%
$31,356.19131
GARRETTSON GARRETT Adirector
39441
0.2245%
$27,450.9452
+27.28%
Devi Nandini
10420
0.0593%
$7,252.3230
<0.0001%
Caldwell Barry GPresident and CEO
6000
0.0342%
$4,176.0010
<0.0001%
FITCH SANFORDdirector
0
0%
$041
+5.46%
*Gray background shows insiders who have made transactions during last year

IRIX Institutional Investors: Active Positions

Increased Positions8+28.57%427,175+15.22%
Decreased Positions10-35.71%158,633-5.65%
New Positions4New372,721New
Sold Out Positions2Sold Out19,269Sold Out
Total Postitions26-7.14%3M+9.57%

IRIX Ownership Change vs Market

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
Paragon Associates & Paragon Associates Ii Joint Venture$1,170.005.88%1M00%2025-09-30
Vanguard Group Inc$677.003.4%578,711-7,102-1.21%2025-09-30
Renaissance Technologies Llc$455.002.29%389,060+10,300+2.72%2025-09-30
Amh Equity Ltd$216.001.08%184,230-5,770-3.04%2025-09-30
Geode Capital Management, Llc$156.000.78%133,059+1,292+0.98%2025-09-30
Citadel Advisors Llc$128.000.64%109,473+78,302+251.2%2025-09-30
Apexium Financial, Lp$118.000.59%100,529+34,834+53.02%2025-09-30
Susquehanna International Group, Llp$66.000.33%56,470+17,834+46.16%2025-09-30
Goldman Sachs Group Inc$56.000.28%47,793+47,793New2025-09-30
State Street Corp$52.000.26%44,71800%2025-09-30

Financial Ratios

Summary
Comparison with Competitors

Price to Earnings

Price/Earnings to Growth

Price to Sales

Price to Book

Price/Free Cash Flow

Analyst Recommendations

Analyst Price Targets

Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.